Truist Financial Corp Reduces Stock Holdings in Chemed Corporation $CHE

Truist Financial Corp decreased its holdings in Chemed Corporation (NYSE:CHE) by 25.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,346 shares of the company’s stock after selling 1,795 shares during the period. Truist Financial Corp’s holdings in Chemed were worth $2,287,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CHE. Smartleaf Asset Management LLC lifted its stake in Chemed by 71.4% in the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after acquiring an additional 25 shares during the period. First Horizon Corp purchased a new stake in Chemed in the third quarter worth $31,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in Chemed in the third quarter worth $45,000. Danske Bank A S lifted its stake in Chemed by 250.0% in the fourth quarter. Danske Bank A S now owns 140 shares of the company’s stock worth $60,000 after acquiring an additional 100 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after buying an additional 76 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Stock Performance

Shares of Chemed stock opened at $422.71 on Thursday. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $5.61 billion, a P/E ratio of 23.04, a P/E/G ratio of 1.57 and a beta of 0.54. The business has a fifty day simple moving average of $396.27 and a two-hundred day simple moving average of $425.23. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $583.96.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The business had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. During the same quarter last year, the firm posted $5.63 earnings per share. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. On average, equities analysts forecast that Chemed Corporation will post 22.3 earnings per share for the current fiscal year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 13th. Stockholders of record on Monday, February 23rd were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, February 23rd. Chemed’s dividend payout ratio (DPR) is presently 13.08%.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Oppenheimer cut their price objective on Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Royal Bank Of Canada lifted their price objective on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $501.50.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.33% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.